Tirzepatide for weight loss in children aged 6 to under 12
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests a once-weekly medication called tirzepatide to help children aged 6 to under 12 with obesity lose weight. It compares the medication to a placebo (inactive shot) to see if it safely helps with weight loss in this age group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The child must be 6 to under 12 years old at the start of the study.
- The child must weigh at least 88 pounds (40 kilograms).
- The child must have obesity, defined as a BMI in the 95th percentile or above for their age and sex.
- The child must have tried a structured diet and exercise program for at least 3 months without enough success.
- The child cannot have type 1 diabetes, severe eye problems from diabetes, or a personal or family history of a rare thyroid cancer.
- The child cannot have a weight-loss surgery planned or done, or have obesity caused by another medical condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called tirzepatide (a once-weekly injection) to help teenagers with obesity and related health conditions lose weight. It aims to see if the drug is safe and effective for this age group.
This study tests a medicine called tirzepatide to see if it helps people with overweight or obesity lose weight, whether or not they also have type 2 diabetes. Tirzepatide is given as an injection and works on hormones that control appetite.
This study tests a medication called tirzepatide (a daily injection) to help people who haven't lost enough weight after weight-loss surgery. If you fit the criteria, the medication may help you lose more weight healthily.
This trial tests if tirzepatide is more effective than standard obesity treatments for adults who have a BMI between 30 and 35 and one weight-related health condition, but do not have diabetes. The goal is to help you lose weight.
This Phase 2 study tests whether tirzepatide can improve how your body handles fat (especially in people with overweight or obesity) and reduce fat-related “lipotoxicity.” It may help with body fat function and related health markers, but you must meet specific health and medication rules.
This study tests a medication called tirzepatide for people with type 1 diabetes who also have overweight or obesity. Tirzepatide may help with weight loss and blood sugar control, and you'll use a continuous glucose monitor throughout the study.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.